Grants and Contributions:
Title:
COVID19 Rapid Response - BOLD-100: A first in class therapeutic for COVID-19
Agreement Number:
961802
Agreement Value:
$1,464,715.00
Agreement Date:
Nov 25, 2020 - Dec 31, 2021
Description:
BOLD-100 is a first-in-class, clinical-stage investigational therapy being developed for the treatment of patients with cancer and viral infections, including COVID-19. BOLD-100 has previously been shown to have antiviral activity against SARS-CoV-2 in an vitro model. This project focuses on completing the preclinical data package, preparing for clinical trial in COVID-19, and supporting manufacturing.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6C 1E1
Reference Number:
172-2020-2021-Q3-961802
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
748003712
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Amendment Date
Sep 27, 2021
Recipient's Legal Name:
Bold Therapeutics Inc.
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: